We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a marked change in policy, the U.S. will send an estimated 4 million doses of AstraZeneca (AZ)/Oxford University’s COVID-19 vaccine to Canada and Mexico, according to a White House press briefing yesterday. Read More
The FDA is preparing to conduct what it’s calling the first-ever systemic study examining how pharmaceutical brand names influence perceptions about drug efficacy. Read More
A federal judge has granted Eli Lilly’s request to halt an HHS final rule for its 340B drug discount program, siding with the drugmaker in finding that the department didn’t follow rulemaking requirements or give enough time for comment. Read More
A U.S. District Court has dismissed major accusations made in a high-stakes lawsuit brought by Minnesota Attorney General Keith Ellison alleging that three big drugmakers engaged in price gouging of diabetes drugs, thus violating the Racketeer Influenced and Corrupt Organizations (RICO) Act. Read More
In a revision of its Emergency Use Authorizations (EUAs) for Eli Lilly’s and Regeneron’s antibody combination therapies for COVID-19, the FDA is requiring the companies to assess the therapies against the mutant strains of the SARS-CoV-2 virus. Read More
The FDA has launched a new online dashboard for adverse event reporting of COVID-19 products that have received Emergency Use Authorizations (EUAs). Read More
HHS announced that it will restrict distribution of Eli Lilly’s COVID-19 antibody therapy, bamlanivimab, in three states because of concerns about its effectiveness against a variant strain of the virus first identified in California. Read More
A study by researchers at the University of Utah and other universities found that payments for neurology drugs under Medicare Part D saw a substantial hike over five years despite only a small bump in the number of claims. Read More